Dermatologist or Clinical Immunologist is required every six months. Clinical effectiveness of Ig therapy can be demonstrated by: Further improvement in ulcer(s) AND Once disease activity is controlled by evidence of healing/ improvement in all ulcers, a trial off therapy should be considered A trial off therapy should be considered when disease activity is controlled by evidence of signs of healing/improvement in all ulcers. Treatment should be substituted with a combination of oral corticosteroids and an immunosuppressive steroid sparing agent at appropriate doses or biologic therapy (unless contraindicated) until ulcers have healed. Ig should be if recurrence of disease activity occurs in spite of these measures. Dose Induction dose: 2 g/kg divided Dosing has been defined with three Severe PG when immunosuppressant and biologic therapy is over three days. months’ treatment at 2 g/kg to either ineffective or inappropriate due to unacceptable side determine whether there has been a effects. Maintenance therapy: 1–2 g/kg clinical response and then divided over two days, monthly Initial Dose– 2 g/kg in divided dose over 3 days, followed by two commencement on maintenance for 4–6 months. further monthly treatments of 1-2 g/kg therapy. A range in maintenance dose is provided to support the weaning of Maintenance Dose – 0.5 to 2 g/kg in single or divided doses IVIg should be ceased in patients from Ig treatment. monthly. patients who fail to respond after three cycles. The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient. Refer to the current product Refer to the current product information sheet for further
Dermatologist or Clinical Immunologist is required every six months. Clinical effectiveness of Ig therapy can be demonstrated by: Further improvement in ulcer(s) AND Once disease activity is controlled by evidence of healing/ improvement in all ulcers, a trial off therapy should be considered A trial off therapy should be considered when disease activity is controlled by evidence of signs of healing/improvement in all ulcers. Treatment should be substituted with a combination of oral corticosteroids and an immunosuppressive steroid sparing agent at appropriate doses or biologic therapy (unless contraindicated) until ulcers have healed. Ig should be if recurrence of disease activity occurs in spite of these measures. Dose Induction dose: 2 g/kg divided over three days. Maintenance therapy: 1–2 g/kg divided over two days, monthly for 4–6 months. IVIg should be ceased in patients who fail to respond after three cycles. Refer to the current product Severe PG when immunosuppressant and biologic therapy is either ineffective or inappropriate due to unacceptable side effects. Initial Dose– 2 g/kg in divided dose over 3 days, followed by two further monthly treatments of 1-2 g/kg Maintenance Dose – 0.5 to 2 g/kg in single or divided doses monthly. The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient. Refer to the current product information sheet for further Dosing has been defined with three months’ treatment at 2 g/kg to determine whether there has been a clinical response and then commencement on maintenance therapy. A range in maintenance dose is provided to support the weaning of patients from Ig treatment.
Pyoderma-gangrenosum2017.docx